Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Are Cannabis Outcome and Safety Monitoring ProtocolsĀ forĀ Dementia in Place?Ā 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

As research into medical cannabis expands, health professionals and families are asking how safety and outcomes areĀ monitored, particularly in people living with dementia. While the UK allows specialist prescribing of cannabis-based medicinal products (CBPMs), there areĀ no dementia-specific monitoring protocolsĀ yet approved byĀ NICEĀ orĀ NHSĀ England. However, broader safety frameworks for controlled medicines do apply.Ā 

Can medical cannabis be accessed legally for womenā€™s health?

Current Clinical Oversight 

Under the Misuse of Drugs Regulations 2001, all cannabis-based products are Schedule 2 controlled drugs. This means any prescription, storage, and administration must follow strict NHS and CQC oversight procedures (NHS England, 2023). 

Specialist doctors listed on the General Medical Councilā€™s Specialist Register are the only clinicians legally authorised to prescribe these medicines. For dementia, all use is considered off-label and must involve ongoing clinical review. 

General Safety Monitoring Standards 

Although NICE has not published dementia-specific protocols, safety monitoring follows existing frameworks for controlled or psychoactive medicines. According to NICE NG144 and NICE SC1, care teams must: 

  • Record all doses on aĀ Medication Administration Record (MAR).Ā 
  • Monitor for sedation, confusion, agitation, and falls.Ā 
  • DocumentsĀ changeĀ in mood, sleep, appetite, and pain response.Ā 
  • Report any suspected side effects to theĀ Yellow Card SchemeĀ via the MHRA.Ā 

These measures form the basis of outcome tracking when cannabis is prescribed in specialist dementia research or symptom management programmes. 

Role Of the CQC And Clinical Ethics 

The Care Quality Commission (CQC) oversees controlled drugs management across all registered care settings. Its Controlled Drugs Annual Report 2024 highlights the need for robust audit trails, staff training, and clear reporting lines to local Controlled Drugs Accountable Officers (CDAOs). 

Ethically, monitoring must comply with the Mental Capacity Act 2005, ensuring decisions about continued cannabis use reflect best-interest discussions and informed consent. The Alzheimerā€™s Society emphasises that families and carers should be involved in evaluating behavioural and quality-of-life outcomes. 

Research Monitoring Initiatives 

The STAND trial at Kingā€™s College London, supported by Alzheimerā€™s Research UK, is currently evaluating Sativex (1:1 THC: CBD) for agitation in dementia. Participants undergo structured monitoring for cognitive change, sleep, and safety, which may inform future national guidance. 

Clinical Bottom Line 

  • No national dementia-specific cannabis monitoring protocols exist.Ā 
  • GeneralĀ controlled-drugĀ andĀ NICE SC1Ā procedures apply to all CBPMĀ use.Ā 
  • Continuous review andĀ MARĀ documentation are mandatory.Ā 
  • Clinical outcomes should include cognition, mobility, and behaviour tracking.Ā 

Educational Context: AlleviMed 

AlleviMed provides educational resources explaining how clinicians monitor safety and outcomes when prescribing medical cannabis under UK regulation. It promotes best practice in documentation, communication, and ethical oversight. 

Takeaway 

Cannabis use in dementia requires individualised monitoring, not standard protocols. Until NICE issues dementia-specific guidance, care teams must rely on existing controlled-drug frameworks, specialist supervision, and person-centred observation to safeguard outcomes and wellbeing. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Masterā€™s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.Ā 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.Ā 

Categories